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 Opium and the People: The prescription psychopharmaceutical epidemic in historical 
context 
“The need for frequent chemical vacations from intolerable selfhood and repulsive 
surroundings will undoubtedly remain” 
Aldous Huxley, Doors of Perception, 1954 
 
 
The modern prescription drug epidemic 
Around the world people are using more and more prescription drugs, and a large proportion 
of these are issued for mental disorders or distress. Antidepressants like Prozac and Paxil 
(Seroxat), and antipsychotics like Zyprexa have been among the best-selling agents of the last 
few decades. The number of prescriptions issued for antidepressants in England rose by 10% 
a year between 1998 and 2010, and numbers are still rising (Ilyas & Moncrieff, 2012). 
Currently nine per cent of the United Kingdom (UK) population are taking antidepressants at 
any one time, slightly higher than the European average of 7.2% (Lewer et al, 2015). In the 
United States 11% of people over the age of 12 take antidepressants, including almost a 
quarter of women in their 40s and 50s (Pratt et al, 2011).  
 This is a trend that is occurring in other parts of the world too, with prescriptions for 
antidepressants now rising faster in middle income countries like Brazil and China than in the 
UK and United States of America (USA) (Busfield, 2010).  Prescriptions for a host of other 
drugs from antipsychotics to pregabalin are also rising, prescribed for a plethora of new and 
newly expanded mental conditions, from social anxiety disorder to bipolar disorder (Ilyas & 
Moncrieff, 2012). Several countries are also experiencing an increase in the use and abuse of 
opioid painkillers, with rising prescriptions occurring in the United States, the United 
Kingdom, Australia and New Zealand. More people are addicted to, and die from prescribed 
opiates in the United States at the moment than from heroin (Lyapustina & Alexander, 2015).  
Most of these drugs are prescribed and taken for long periods of time. Two thirds of people 
taking antidepressants in the US have been taking them for more than two years, for example 
(Pratt et al, 2011). Many people take sleeping pills and anti-anxiety agents on a long-term 
basis, especially the elderly (Hope, 2013), and drugs like antipsychotics and ‘mood 
stabilisers’ are usually prescribed for years at a time. So it is not just that more people are 
reaching out for pharmaceutical help at a time of crisis; more people are coming to depend on 
these drugs in their day to day lives for months, years and often for life.  
Why and how have we become such a drug-dependent a society? The answer lies partly in 
the fact that mainstream medicine, psychiatry and the mental health disciplines do not 
recognise the real nature of the drugs that are prescribed to treat mental health problems. In 
particular, they do not recognise that drugs like antidepressants and antipsychotics are 
psychoactive, or mind-altering substances. Prescription drugs with mind-altering effects are 
what I refer to as ‘psychopharmaceuticals.’  
Psychoactive drugs 
In professional circles, the term ‘psychoactive substance’ is mainly associated with 
recreational drugs like alcohol and cocaine. Antidepressants are simply described as drugs 
that are used to treat depression, or anxiety, or various other problems. Antipsychotics are 
described as drugs to treat schizophrenia or psychosis, or they are referred to ‘mood 
stabilisers’ which are meant to treat ‘bipolar disorder’.  
A psychoactive substance can be defined as a chemical that produces an altered mental state 
and associated changes in behaviour due to its effects on the central nervous system. 
Although we are most familiar with the psychoactive effects of recreational drugs like 
alcohol, drugs prescribed to treat mental disorders, including drugs classified as 
antidepressants, antipsychotics, anxiolytics, stimulants and drugs such as lithium and 
anticonvulsants used to treat bipolar disorder, also modify normal mental processes and 
behaviour. These alterations are independent of any effects they may or may not have on 
hypothetical underlying abnormalities or disease processes.  
Just like the various substances that are used recreationally, each prescribed psychoactive 
drug or psychopharmaceutical, produces a distinctive altered mental and physical state, 
whose characteristics depend on the pharmacological properties of the particular drug. Some 
prescribed drugs such as stimulants (including amphetamine and methylphenidate, otherwise 
known as Ritalin) and benzodiazepines (including diazepam, brand name Valium, temezepam 
and lorazepam, brand name Ativan) produce pleasurable effects, and, for this reason, licitly 
and illicitly obtained supplies may be used recreationally and excessively. Others are 
experienced as unpleasant. This is most notably the case with the neuroleptic or antipsychotic 
drugs like chlorpromazine (brand names Thorazine or Largactil), haloperidol (Haldol), 
olanzapine (Zyprexa) and quetiapine (Seroquel), but tricyclic antidepressants and lithium are 
also generally disliked by volunteers (Dumont et al., 2005; Judd et al., 1977a). Selective 
serotonin reuptake inhibitors (SSRIs) like fluoxetine (Prozac) and paroxetine (Seroxat or 
Paxil) generally have weaker psychoactive effects, but the effects are found to be unpleasant 
when noticed (Dumont et al, 2005). The fact that these drugs are not associated with 
euphoria, and therefore do not usually induce craving or become drugs of abuse, does not 
make them any less ‘psychoactive’ than recreational drugs, nor does it exclude them from 
inducing physical dependence.  
Table 1 summarises scientific literature and user descriptions of the principle drug-induced 
mental alterations associated with the major classes of drugs prescribed for mental disorders 
during use of the drug. Each type of drug also produces characteristic withdrawal effects after 
it has been stopped. It is important to remember, however, that within each so-called class of 
drugs there are different types of agent, with varied and distinctive pharmacological profiles 
and that agents between and across classes differ in the strength of their effects.    
Nevertheless, a property that is common to many mind-altering drugs is a flattening out of 
emotional experience. Opiates, neuroleptics and SSRIs, for example, in different ways render 
emotions less intense, and create a state of emotional disinterest or detachment. This is in 
contrast to drugs like alcohol and benzodiazepines which can intensify emotions during 
intoxication. Regardless of their differing impact on emotions, however, all psychoactive 
substances impair higher brain functions to a greater or lesser extent, as American 
psychiatrist, Peter Breggin, points out (Breggin, 2008). Mind-altering drugs reduce our 
sensitivity to our surroundings, especially to subtle environmental cues, such as the behaviour 
of other people. They diminish our ability to react creatively, to take initiative and think 
laterally. They make us less aware of other people’s emotions, and less able to engage with 
their concerns. Of course this depends on the strength of the drug. A small dose of caffeine or 
nicotine makes little difference, but being under the influence of alcohol, as we know, can 
seriously impair a person’s judgement about their situation. Moreover, we are often unaware 
of this impairment while we are under the influence of a mind-altering drug, a phenomenon 
that Breggin refers to as the ‘spell-binding’ effects of drugs (Breggin, 2008). It is only after 
we have stopped the drug, and its effects on the body have completely worn off, that we are 
able to properly assess how it affected us.  
Drugs that produce euphoria are generally acknowledged to have psychoactive effects, at 
least after patents expire and profits fall. This is often associated with concern about over-use, 
and prescribing of benzodiazepines is now discouraged in many countries, for example. 
However, the disease-centred idea can obscure these effects for as long as commercial or 
professional incentives exist. Thus although the pleasurable and energising effects of 
amphetamine are well-recognised, they are rarely mentioned in the context of treating 
attention deficit hyperactivity disorder (ADHD), for example, as this is an area of growing 
professional interest and many treatments are still on patent. Pregabalin, a drug introduced 
into Europe in 2004 and marketed for the treatment of pain and anxiety, has been a controlled 
substance in the United States since 2004. In the United Kingdom, prescriptions have soared 
over the last 10 years, and it has become one of the most costly drugs prescribed in the 
National Health Service (Prescribing and Medicines Team, 2015). Warnings about its 
potential for misuse were only issued in December 2014 in England, however, and its use still 
does not attract the opprobrium attached to the prescription of opiates or benzodiazepines for 
the same situations (Public Health England, 2014).   
Author Richard DeGrandpre suggests that psychoactive drugs are currently divided into 
socially sanctioned and socially disreputable substances:  ‘angels and demons’ (see Table 2) 
(DeGrandpre, 2006). The angels are those drugs that are considered to be specific treatments 
for underlying medical conditions, and whose use is endorsed and promoted. The ‘demons’ 
are drugs that are used primarily for their mind-altering properties, whose use is either illegal 
or disparaged. Alcohol, as western society’s principle recreational drug, is tolerated, if not 
actively promoted. The division is fluid, however. Benzodiazepines were first represented as 
specific anti-anxiety agents, but as their pleasurable effects and addictive potential became 
clear, they were relegated to the status of ‘demons’. Amphetamine, whose use as a 
prescription drug declined dramatically in the 1970s following the imposition of tighter 
controls, is enjoying a revival of its reputation as a specific treatment for adult ADHD.  
The category a drug falls into is not determined by reliable evidence of the effectiveness of 
drugs as treatments for underlying diseases or abnormalities, nor by the level of harm they 
can induce. Despite the ubiquity of the myth of the chemical imbalance, it has never been 
demonstrated that drugs work by targeting abnormal physiological or biochemical processes 
(Moncrieff, 2008a). There is, moreover, no evidence that there are specific biochemical 
imbalances associated with the particular mental disorders we currently identify and 
diagnose. Evidence never concurred with the serotonin hypothesis of depression - it was a 
figment of the pharmaceutical industry’s marketing departments (Lacasse & Leo, 2005; 
Moncrieff, 2014). The dopamine theory of schizophrenia is also at odds with most of research 
results, and the non-specific role of dopamine in arousal and stress, as well as uncontrolled 
effects of prior antipsychotic drug treatment, are likely to account for the few positive 
findings (Moncrieff, 2009).  
 
Consequences of the psychopharmaceutical epidemic  
Has the epidemic use of psychoactive drugs on prescription made us happier and healthier? 
Are we a more stable and productive society as a consequence of all the antidepressants we 
are consuming? Does the use of these mind-altering chemicals enable people to live more 
contented and fulfilling lives?    
Although some of these drugs may be useful for some individuals in some situations, there is 
no evidence that the sort of mass prescribing that exists at present has tangible benefits for 
most individuals or society.  
The evidence on which the use of these drugs is based consists of randomised controlled 
trials, in which an active drugs is compared with a placebo. Outcomes are judged by 
comparing scores on specially devised rating scales, which are supposed to measure the 
symptoms of the disorder in question. None of these scales has ever been shown to really 
capture the problem it is meant to measure (if indeed that is possible), and the differences 
between the drug and the placebo are usually quite modest. In trials of antidepressants for 
example, meta-analyses find that the difference in scores on the commonly used Hamilton 
Rating Scale for Depression are less than 2 points, where the maximum score is 54 (Kirsch et 
al, 2002). This difference is much smaller than the difference that clinicians identify as 
indicating even modest improvement (as measured by the Clinical Global Impressions scale). 
In fact, clinicians do not notice any difference at all at differences on the Hamilton scale of 3 
points or less (Moncrieff & Kirsch, 2015).   
Few studies have looked at objective measures of the outcome of drug treatment, and where 
they have done so, the evidence suggests that drug treatment may be harmful to many 
people’s prospects of recovery. Studies of working people with depression have found, for 
example, that people who take antidepressants have more time off work than those who do 
not (Dewa et al, 2003). Some of the difference is likely to be attributable to the fact that 
people with more severe disorders are more likely to be offered and accept drug treatment, 
but nevertheless, the findings do not provide any support for the idea that antidepressant 
treatment improves work performance. The correlation between rising antidepressant use and 
disability claims for depression and anxiety, particularly when claims for other medical 
conditions are falling, provides further evidence that mass antidepressant use does not 
improve the mental health of the population, and may make it worse (Figure 1).  
Antipsychotic drugs, with their neuro-suppressant effects, reduce acute psychotic symptoms 
and distress, but, although long-term drug treatment is well-established and recommended 
practice for people with disorders like schizophrenia, the ultimate benefits of this remain 
uncertain. Most studies of long-term treatment have focused on measuring the risk of having 
a ‘relapse’ of the underlying condition, and few have looked at social functioning, 
independence or quality of life. Moreover, few studies have followed people up for more than 
one or two years. A non-randomised follow-up study suggested that people who took 
continuous medication might have a worse outcome than those who did not, but the 
difference between people who used drugs continuously and those who did not may be 
explained by differences in the severity of the underlying problem (Harrow et al, 2012).  
However, a long-term follow-up of participants from a randomised controlled trial supports 
the idea that taking antipsychotic medication continuously for long periods may lower your 
chances of making a good recovery. The study consisted of a comparison between 
antipsychotic maintenance treatment for people with a first episode of psychosis, with a 
gradual and supported programme of antipsychotic reduction and discontinuation. Seven 
years after the programme begun, people in the group randomised to the antipsychotic 
discontinuation programme were over twice as likely to show a full social recovery as people 
allocated to maintenance treatment (Wunderink et al, 2013). Relapses, which were initially 
higher in the antipsychotic discontinuation group, evened out over the 7-year follow-up. Only 
20% of participants in the antipsychotic discontinuation group stopped their medication 
completely and remained off it, with many more stopping and going back on to medication, 
or never completely stopping at all. Conversely, some people in the maintenance group 
successfully reduced or stopped their medication. Nevertheless, overall the group that was 
originally randomised to the supported antipsychotic reduction strategy was more likely to 
have stopped their medication or be taking very low doses by the time of follow-up. The 
study appears to suggest that even with psychotic disorders, the standard practice of taking 
medication for years on end reduces people’s chances of making a meaningful recovery.  
The benefits of long-term use of benzodiazepines, ADHD treatments and drugs prescribed for 
bipolar disorder have also not been established (Moncrieff, 2008a).  
None of these types of drug is innocuous. Antipsychotics have well-known and potentially 
devastating adverse effects, including the sometimes irreversible neurological condition 
known as tardive dyskinesia, weight gain, diabetes, sexual dysfunction and cardiac toxicity 
leading to an increased risk of sudden cardiac death (Salvo et al, 2016). Antidepressants such 
as the SSRIs are less debilitating overall, but can also cause apathy, sexual dysfunction and a 
state of agitation that has been associated with increased suicidal ideation and behaviour in 
young people in particular (Safer & Zito, 2006). Although there is little official data, patients 
reports consistently indicate that stopping the drugs can lead to unpleasant and sometimes 
incapacitating withdrawal symptoms, which can occasionally persist for months and even for 
years (Fava et al, 2015).   
There is little evidence, therefore, that the widespread use of psychopharmaceuticals has any 
objective benefits, and plenty of reasons to be concerned about their effects. Hence, 
explanations for their popularity must lie outside the scientific arena. Looking at the history 
of humankind’s relationship with mind-altering substances of all sorts helps to put the current 
situation in context, and points to some universal drivers of this activity.    
History of psychoactive drug use 
Psychoactive drugs have been a part of life in most societies and communities throughout 
history. They have been used for pleasure, to dull physical and emotional pain, to increase 
concentration and endurance and to induce states of religious ecstasy (DeGrandpre, 2006).  
Up until the late 19th century, there were no restrictions on the sale and availability of any 
sort of substance (except for price) and you could buy opium and cocaine-containing 
preparations from the corner shop, along with your groceries.  
For centuries prior to our own time, medicinal and ‘recreational’ use of psychoactive 
substances was not clearly differentiated. In a world where medical fees were beyond the 
means of most ordinary people, long before the formation of the NHS and other socialised 
forms of health care, people treated themselves as far as they could, using the drugs that were 
available to them. The intoxication produced by alcohol, for example, was used for its 
anaesthetic effects, as well as for pleasure. Opiates (opium, morphine and heroin), which 
effectively deaden physical pain and emotional anguish, were widely used to dull the physical 
and emotional strains of the labouring classes during the industrial revolution. Many 
substances were sold as ‘tonics’ which were advertised as promoting both physical health and 
mental wellbeing.  
The use of psychoactive substances only came to be viewed as a social problem under 
particular social and economic conditions. In the medieval world, the peasants could get as 
drunk as they liked, and no one suffered much but themselves. When wage labour and factory 
labour became the norm, it suddenly mattered if labourers were intoxicated and less 
productive than they might be. Life in emerging industrial Britain was also more than 
conducive to heavy drinking and drug use. Dislocated from home and family, working 12 
hours a day (or more) for seven days a week, alcohol and drugs provided the worker with a 
quick and easily accessible escape, maybe the only one he or she could hope for.   
The controls that were placed on the use of mind altering substances from the beginning of 
the 20th century could not stamp it out, however. Prohibition of alcohol in the United States 
was a resounding failure, and although the availability of opium was restricted, the 
pharmaceutical industry started to produce a new array of mind-altering chemicals. As 
options for self-prescribing became more limited, the use of mind-altering drugs came 
increasingly under the control of medical practitioners.  Women in particular, less inclined to 
drown their sorrows in drink than men, started to go to the doctor to obtain a chemical salve 
for difficult and unfulfilling lives. As medical practitioners started to control the availability 
of such substances, the problems for which these drugs were used were transformed into 
medical problems. As this occurred the nature of the drugs and their mind-altering properties 
became obscure, and the reasons why people were using them were concealed beneath a 
medical mythology.  
The problematisation of drug use    
In medieval and Tudor England, heavy drinking was an accepted part of rural life. Weak beer 
was consumed instead of water by all the family on a daily basis, but festivals and holidays, 
of which there were many, were occasions for drinking to inebriation. Drunkenness was not 
regarded as problematic in pre-industrial society, and the country people were left to drink as 
they pleased.    
It was in the 18th century, when the increasing urban population took to drinking gin in large 
quantities, that concern about alcohol use emerged. Hogarth’s famous engraving, Gin Lane, 
indicates the moral outrage that had started to form around the drinking habits of the poor.  
Freed from the customs and obligations of rural life and displaced into the exploitative 
environment of early capitalist cities, the nascent working class turned to the instant oblivion 
provided by the newly imported, super-strength liquor, gin. Gin was blamed for rocketing 
rates of crime, prostitution and debt, and the upper classes lived in fear of a breakdown of law 
and order, as well as bemoaning the decline in the nation’s productivity. The Gin Acts of the 
18th century were the first legislative attempts to control the people’s use of mind-altering 
chemicals (Gately, 2008).  
A similar same story played out with opium, which was widely used by all classes during the 
19th century. The medicinal and recreational qualities of opiate drugs are particularly difficult 
to disentangle, and addiction to opium was likely common among working people who used 
it either to alleviate the pain of physical ailments, to relieve emotional strain or for 
enjoyment. Cocaine in various preparations was also widely available and vigorously 
promoted in the 19th century. Vin Mariani, a popular patient medicine developed in 1863, was 
one of a number of cocaine containing preparations on the market in Europe and the United 
States. It was made from a mixture of Bordeaux wine and coca leaves, the ethanol in the wine 
extracting the cocaine from the coca leaves. It was endorsed by Pope Leo XIII, who awarded 
it a Vatican gold medal, and appeared on advertisements which claimed the drink restored 
‘health, energy, strength and vitality’ (Wikipaedia, 2015). The performance enhancing 
properties of cocaine were widely recognised, and used to promote another cocaine-
containing preparation, Coca-Cola. 
Through the course of the 19th century concerns mounted about working class opium use. The 
accidental poisoning of children with opium or laudanum (a combination of opium and 
alcohol) fuelled public health campaigns against the drug in Britain (Berridge, 1977). These 
coincided with rising opposition to the British opium trade with China. The United States 
banned the importation of opium for smoking from 1909 with the passing of the Opium 
Exclusion Act and in 1912 the first of a series of international treaties obliged signatories to 
restrict importation of opium to medicinal preparations. In the United Kingdom drugs were 
blamed for the dissipation of soldiers during the first world war, and use of opium, cocaine 
and marijuana was made illegal by the Defence of the Realm Act 1916, which was later 
extended into peacetime as the Dangerous Drugs Act, 1920 (Berridge, 1977; Cockburn & St 
Claire, 1998).  
The puritanical movement against the use of mind-altering substances culminated in national 
prohibition of the liquor trade in the United States, which came into effect in 1920 and lasted 
13 years. Prohibition is widely acknowledged as a piece of class legislation, stimulated by 
concerns over working class drinking habits. It was the result of a concerted campaign by the 
Anti-Saloon League and its aims were never to abolish the consumption of alcohol entirely, 
but to shut down the saloon. Possession and consumption of alcohol were not prohibited, only 
its commercial trade, and those with the foresight and the resources were free to drink alcohol 
they had stored before prohibition came into force. When the Great Depression hit, and the 
masses needed pacifying, prohibition was finally repealed (Burnham, 1968).   
Psychoactive drug use in the 20th century  
As avenues for self-initiated use of psychoactive substances closed down, the medical 
profession and the pharmaceutical industry stepped into the breach. Small-scale chemists and 
pharmaceutical companies started to increase the scale of their development activities, 
production and marketing in the early 20th century, transforming into the large-scale modern 
industry we recognise today (Liebenau, 1987).    
Barbiturate drugs first became available in 1903, and although they revolutionised 
anaesthesia and the treatment of epilepsy, they were most widely prescribed for anxiety and 
insomnia. Amphetamines, available as tablets from 1937, were prescribed for the treatment of 
mild depression  or ‘neurosis’. They were issued to pilots during world war II, and soon 
started to be used as diet pills (Rasmussen, 2006).  
In the mid 20th century use of prescription stimulants and sedatives was rife. In 1955, the 
quantity of barbiturates being used in the USA was sufficient for the treatment of 10 million 
people on a continuous basis for a whole year, representing 6% of the population of the time, 
or 8.6% of the adult population (Glatt, 1962). Miltown, a barbiturate-like drug launched in 
the United States in 1955, was one of the first individual block-buster drugs. At the height of 
its popularity, apparently, demand for the drug was so high that pharmacies frequently ran out 
of supplies, hanging signs on their doors saying ‘Out of Miltown’, ‘More Miltown tomorrow’ 
(cited in Metzl, 2003).  It was marketed for everything and everyone. Advertisements 
recommend it for ‘the tense nervous patient,’ ‘the agitated senile patient,’ ‘the problem child,’ 
‘the alcoholic’ (Wallace Laboratories, 1964) and suggest that with the use of Miltown, 
‘pregnancy can be made a happier experience’ (Wallace Laboratories, undated).  
By the 1960s, amphetamines and other stimulants (e.g. Ritalin) were also in high demand. In 
the UK, a survey conducted in 1960 found that the quantities of amphetamine being 
prescribed were enough to supply 1% of the whole population with twice daily doses on a 
long-term basis. Eighty five per cent of prescriptions were issued to women, mostly those 
between the ages of 36 and 45. A third of prescriptions were issued for weight loss, a third for 
depression or anxiety and a third for a medley of vague complaints including tiredness, pain 
and psychosomatic complaints (Kiloh & Branden, 1962). By 1971, 5% of the total US 
population were being prescribed amphetamines (Rasmussen, 2008).   
Benzodiazepines were introduced in the early 1960s, and soon became popular as a safer 
alternative to barbiturates (they are less dangerous in overdose than the highly toxic 
barbiturates). By the 1970s, benzodiazepines were being used regularly by 8% of the UK 
population, with 14% using them at least once a year (Balter et al, 1974). Again they were 
prescribed for a wide range of vague complaints including ‘nerves’ and unexplained physical 
symptoms (Lader 1978).  
Drug advertising 
The massive advertising campaigns that promoted these drugs played on the psychological 
insecurities of their age, and were mostly targeted at women. Advertisements for 
amphetamine paraded images of stylish, well-dressed women, suggesting the state that 
women should aspire to. ‘Stay fit and slim’ calls a 1940 advertisement, featuring the picture 
of an attractive young woman (Amphetamine advertisement, 1940). Ritalin ‘helps relieve 
chronic fatigue and apathy quickly,’ claims another, featuring a picture of a tired looking 
woman with a vacuum cleaner, who will presumably soon be vigorously vacuuming her 
house with the help of Ritalin’s ability to restore ‘alertness, enthusiasm and drive’ (Ciba, 
1970).  
Barbiturates, Miltown and the benzodiazepines were promoted as alleviating the burdens of 
the post-war housewife. A 1960s advertisement for Miltown announces it’s usefulness for 
‘battered parent syndrome,’ for women who are ‘physically and emotionally over-worked, 
over-wrought and ...overwhelmed’ (Wallace Laboratories, 1967). Tranquilisers, as they 
became known, were a means of managing the cultural anxieties of a world in which gender 
roles were changing dramatically (Metzl, 2003). During the second world war, women had 
joined the workforce and played a full role in public life, but in the 1950s, they were 
increasingly encouraged to retreat to the private sphere. The contradictions and frustrations of 
this situation were transformed into the pathology of individual women. The advertisement 
for ‘battered parent syndrome’ goes on: 
‘What went wrong. Is parenthood something other than the rosy fulfilment pictured by the 
women’s magazines?  Is anxiety and tension fast becoming the occupational disease of the 
homemaker?  
Some say it is unrealistic to educate a woman and then expect her to be content with the Cub 
Scouts as an intellectual outlet.  
Or to grant that she is socially, politically and culturally equal, while continuing to demand 
domestic and biological subservience. 
Or to expect her to shoulder the guilt-burden of this child-centred age without unravelling 
around the emotional edges. 
Or to compete with her husband’s job for his time and involvement.  
But whatever the causes, the consequences- anxiety, tension, insomnia, functional disorders- 
fill waiting rooms. Sometimes it helps to add Miltown to her treatment- to help her relax both 
emotional and muscular tension. It’s no substitute for a week in Bermuda, or for emotional 
readjustment. But it will often make the latter easier for her, as well as for the physician’ 
(Wallace Laboratories, 1967).   
Advertisements for benzodiazepines continued the themes of frustration and inadequacy. 
Some persuaded doctors that unmarried women or men, or men dominated by women, were 
good candidates for Valium. An advertisement for the benzodiazepine oxezapam, featuring a 
young woman surrounding by brushes and cleaning equipment, suggests to the doctor that 
‘you can’t set her free, but you can make her less anxious’ (Wyeth Laboratories, 1967).  
Feminist writer, Betty Friedan, coined the term the "Problem That Has No Name" for this 
mid-20th century female angst in her famous book, The Female Mystique: 
"The problem lay buried, unspoken, for many years in the minds of American women. 
It was a strange stirring, a sense of dissatisfaction, a yearning [that is, a longing] that 
women suffered in the middle of the 20th century in the United States. Each suburban 
[house]wife struggled with it alone. As she made the beds, shopped for groceries … 
she was afraid to ask even of herself the silent question — 'Is this all?" (Friedan, 
1963, P 15) 
Rock band, The Rolling Stones, also captured the idea of prescription drugs as the panacea for 
the stifled housewife in their famous song Mother’s Little Helper, purportedly written about 
Valium.  
 
The recreational drug scene 
From the 1950s onwards, the prescription of mind-altering drugs for mental health problems 
was paralleled by the rise of the recreational drug scene. Initially the drugs consumed 
recreationally were mostly diverted from medical sources. Amphetamine, barbiturates, and 
the famous mixture of the two, Drinamyl (purple hearts), were the party drugs of the 1950s, 
60s and 70s. As late as the 1970s, the majority of illicitly consumed substances were of 
pharmaceutical origin. In 1972, 80-90% of the stimulants sold on the street in the US were 
products of pharmaceutical firms (Graham, 1972). Imported cannabis, cocaine and heroin 
were also widely used for recreational purposes, and after stricter controls were placed on the 
manufacture of amphetamine, the drug started to be manufactured illicitly in large quantities. 
Nevertheless, the origins of the recreational drug scene lie in the diversion of drugs 
prescribed by medical practitioners. The mass prescription of mind-altering drugs also helped 
to established the appeal of changing one’s mental state. In 1970, US senator Thomas Dodd 
complained that it was the pharmaceutical industry’s ‘multihundred million dollar advertising 
budgets, frequently the most costly ingredient in the price of a pill, have pill by pill, led, 
coaxed and seduced post world war 2 generations into the “freaked out” drug culture 
plaguing the nation’ (Graham, 1972).  
As drug use became increasingly associated with pleasure and expanding consciousness, 
rather than relieving distress, it became a symbol of rebellion. By the late 1960s, illicit drug 
use was strongly associated with the counter-culture- the hippy movement, the anti-Vietnam 
war protests, the 1968 student uprisings etc. Drug use was part of the revolution against 
conservative mores and culture and against the regimented system of capitalist production 
and its associated war machine. Later in the 1970s and 80s, illicit drug use, particularly of 
heroin and later crack cocaine, was associated with the urban underclass created by the 
worldwide recession, and the neoliberal economic policies enacted by Thatcher, Reagan and 
other world leaders.   
In the early 1970s legislation was passed in the US and UK that attempted to put the genie 
back in the bottle.  Amphetamines, along with other drugs like LSD and cannabis, became 
prohibited substances. Legitimate medical uses of amphetamines were restricted to 
narcolepsy and ADHD, production quotas were applied and prescriptions and diversion 
plummeted. Use of illicitly manufactured substances or imported drugs like heroin and 
cocaine rose to fill the gap (Rasmussen, 2008). Meanwhile prescriptions for benzodiazepines, 
not yet identified as ‘demons,’ continued to rise (Lader, 1991).  
 
The professional reaction 
The emerging drug scene presented a challenge to psychiatrists, whose drugs consisted 
entirely of psychoactive substances. To preserve the specialist aura of prescribing, and to 
avoid being seen as drug peddlers, the profession needed to distant itself from recreational 
drug use and present its practice as commensurate with the increasingly sophisticated use of 
drugs in other parts of medicine.  
Up to and including the 1950s, the drugs administered to people with mental health problems, 
were understood to work through the characteristic mental and physical alterations they 
produced, in what I have called a ‘drug-centred’ model of drug action (Moncrieff, 2008a). 
The sedatives administered to the most turbulent psychotic patients were regarded as 
chemical restraints that had no effect on the underlying problem. The stimulants prescribed 
for the depressed housewife were marketed as ‘pep’ pills, much as cocaine had been 
advertised a century earlier. After the 1950s, however, a new understanding of drug treatment 
developed; the ‘disease-centred’ model of drug action. This new model, which persists to the 
present-day, portrays drug treatments as working by rectifying a putative underlying chemical 
or physiological abnormality in the brain. This alleged abnormality, or disease, is assumed to 
produce the mental and behavioural symptoms of a particular disorder. Hence drug 
treatments, according to this model, target the hypothetical biological origins of the 
symptoms of mental disorders.  
In the 1950s, while the drug-centred model still predominated, psychiatrists took an interest 
in the nature of the mental and behavioural alterations their drugs produced. They provided 
detailed descriptions of the effects that early antipsychotics like chlorpromazine had on 
patients and volunteers, including their junior colleagues (Moncrieff, 2013). They compared 
and contrasted the drug-induced states produced by chlorpromazine and barbiturates. 
Similarly, the stimulant-like properties of early antidepressants were clearly documented in 
contemporary accounts (Crane, 1956). Over the course of the next two decades these 
observations drop out of the literature, and there is an increasing silence as to the 
psychoactive nature of drugs used in psychiatry. By the 1990s, it ceases to occur to anyone 
that understanding the alterations produced by the new SSRI antidepressants or the atypical 
antipsychotics is important, even despite the fact that they were both promoted as having 
fewer adverse effects and being more ‘tolerable’ than their predecessors.        
The ‘disease-centred’ model emerged alongside the illicit drug scene and enabled 
psychiatrists to present their treatments as specific, illness-targeting treatments, just like the 
drugs that were used in general medicine. By presenting psychiatric drugs as targeting 
underlying abnormalities, the disease-centred model helped to repackage the use of 
psychoactive substances as a bona fide medical treatment, quite distinct from the use of drugs 
in other contexts.  
From the 1960s it became particularly important to distinguish newly introduced psychiatric 
drugs from amphetamines, since the ubiquitous use of the latter was causing increasing 
concern. The stimulant effects of early ‘antidepressant’ drugs started to be played down 
(Moncrieff, 2008b). Discussants at a conference held in 1962 were keen to stress how the 
new ‘antidepressants’ were ‘much more specific’ than stimulants (Goldman, 1966). The 
concept of an ‘antidepressant’ helped cement the medicalisation of psychoactive drug use by 
defining the new drugs by their proposed effects on the presumed biological mechanism of 
depression, rather than their pharmacological properties.   
The disease-centred model was undermined, however, by the continued prolific use of 
benzodiazepines. By the 1980s it was clear that however much they might be trumpeted as a 
specific treatment for anxiety, they were being used for their tranquilising properties, 
prescribed to many people, especially women, in order to numb the difficulties of daily life. 
Moreover, despite official guidelines stating that ‘the true addictive potential of 
benzodiazepines is low’ (Committee on the Review of Medicines, 1980), evidence was 
accumulating to indicate that benzodiazepines were just as addictive as barbiturates or 
opiates. Estimates suggested a quarter of a million people might have become unknowingly 
addicted to medically prescribed benzodiazepines in the UK alone by the 1980s (BBC, 1983, 
cited in Gabe & Bury, 1991). What came to be seen as the ‘tranquiliser problem’ was widely 
covered in the media, with high profile programmes such as That’s Life and Brass Tacks 
dedicating several episodes to the issue (Gabe & Bury, 1991).  
On top of the medical addicts, short-acting benzodiazepines like temezapam rapidly became 
popular among problem drug users, especially people who used or were addicted to opiates. It 
became clear that withdrawal from benzodiazepines was just as difficult, and physically more 
hazardous, than withdrawal from heroin. Benzodiazepine dependence became one of the 
most common indications for admission to drug detoxification and rehabilitation services by 
the 1990s.   
The chemical imbalance 
The scandal over dependence and over-prescribing that erupted in the late 1980s forced the 
pharmaceutical industry to commit itself wholeheartedly to the disease-centred model for 
marketing its new drugs. Formerly, drugs were marketed in various ways. Some 
advertisements presented drugs like antipsychotics as disease-specific treatments, but others 
continued to emphasise the tranquilising properties of drugs like the benzodiazepines. In 
contrast, the 1990s blockbuster ‘antidepressants’ such as Prozac and Paxil were advertised 
not for their mind-altering qualities, but for their ability to reverse an underlying chemical 
imbalance. In this situation it became as important to market the disease as the drug, and 
companies funded ‘disease awareness’ campaigns to encourage people to think of themselves 
as ‘depressed’ (Breggin & Breggin, 1995).   
The chemical imbalance has since become the ubiquitous justification for the prescription of 
mind-altering substances. Despite the fact that it has long been accepted as false, or at least 
unproven, the idea continues to be cited as the basis for the action of drugs in depression, 
bipolar disorder and adult ADHD on company websites and advertisements. Pharmaceutical 
marketing has been extremely effective in creating a new reality, bearing witness to Mary 
Boyle’s suggestion that if you say something enough times, it will become accepted as truth 
(Boyle, 2002).  The message has been so successfully diffused throughout society that most 
members of the general public have been convinced that chemical abnormalities have been 
established in depression and that these abnormalities are corrected by antidepressants. An 
audience of university lecturers and professors whom I spoke to recently were quite 
astounded to find out that this is not, in fact, the case.  
The language may have changed, but the motives remain the same. The target market has 
changed little too. Users of the new prescription drugs are still predominantly middle aged 
women, although increasing numbers of younger people and men have joined them (Lewer et 
al, 2015). In many countries, even treatments for adult ADHD are predominantly prescribed 
to women (Simon et al, 2009). In view of the fact that boys outnumber girls in childhood 
diagnoses by 3 to1, and adult ADHD is supposed to be a continuation of the childhood 
condition, this is a curious pattern. It suggests that far from treating a specific condition, 
drugs prescribed for ADHD, along with antidepressants, new anti-anxiety agents and 
treatments for bipolar disorder, are finding their way into that longstanding niche for the 
treatment of manufactured female inadequacy and discontent. Advertisements still feature 
pictures of the anxious-looking women they are trying to appeal to (Edwards, 2010), and 
others parade images of domestic female contentment, represented by happy-looking women 
with children or women serving food to their male partners (Eli Lilly, 2016).  
 
The pros and cons of transcendence  
Attitudes to the use of mind-altering drugs have changed profoundly over the last half 
century. First the recreational drug scene arrived, in which the use of mind-altering drugs 
became a subversive and rebellious activity. Second, the benzodiazepine crisis revealed the 
extent to which medically prescribed substances were also being used to transport people 
away from a mundane or depressing reality. By the 1980s, the mass drugging of poor and 
unhappy women was no longer socially acceptable.  
Since that time, the new versions of opium and Valium come packaged not with the idea of 
temporary transcendence, but with the idea that the user is biochemically flawed, and in need 
of a chemical fix. We are inherently defective, and our destiny and salvation is in the form of 
a pill.   
This idea enables the mass drugging of the population to continue, and indeed to expand. It is 
this idea that enables powerful psychoactive drugs to be used as a treatment for troublesome 
behaviour in children, for example, which would otherwise no longer be acceptable. The idea 
that drugs are specific and targeted treatments for underlying disorders such as ADHD, 
depression or bipolar disorder provides the justification for the epidemic use of stimulants, 
antidepressants and antipsychotics in children that is sweeping the United States and creeping 
into Europe (Boseley, 2015).   
The pharmaceutical industry knows that what constitutes a medical indication for 
psychoactive drug use is infinitely malleable, and that this malleability can be used to 
capitalise on the ancient human desire to alter one’s mental state. Large swathes of the 
population can be persuaded to view themselves as needing drug treatment for anxiety, 
depression, bipolar or whatever is the flavour of the decade (Healy, 2004). Just as 
governments of the mid 20th century tolerated the widespread use of barbiturates and 
amphetamines, governments of the 21st century have shown no concern about the rapidly 
rising use of antidepressants, antipsychotics and medically prescribed stimulants. Although 
packaged as sophisticated disease-targeting interventions, they fulfil the same role that the 
widespread use of opium and cocaine-containing ‘tinctures’ did in the 19th century. They 
provide the promise of a quick fix, and a mind-altering experience that temporarily removes 
the user from unwelcome thoughts and circumstances.   
The impulse for chemical transcendence is a deeply ingrained and long-standing human 
impulse, and one that is not necessarily harmful. When it is presented as something else, 
however, the natural controls that most human beings can exercise over this impulse may be 
over-ridden. If we are told by a doctor that a drug will simply restore us to some imagined 
state of biochemical normality, its spell-binding effects will be reinforced by a lack of 
awareness of the nature of what we are taking. Our instincts that chemical oblivion should be 
restricted to a few hours, and that being permanently under the influence of mind-altering 
substances is not a good idea, will be suppressed. We are not likely to identify or monitor 
how the substance changes our ordinary thinking and behaviour, and our interactions with the 
world around us.  
The idea that we are chemically flawed is superficially attractive, but profoundly 
disempowering. In the short-term it may provide comfort by locating the source of unwanted 
feelings and responsibility for failure in our biology, but it also suggest that improvements 
and solutions are beyond our capability. Only with expert medical intervention and lifelong 
dependence on chemicals is it possible to ameliorate the disabling defects of a faulty brain. 
People who are fed this message are left in a highly vulnerable state. Once started on 
medication, many become terrified of ever coming off it, and never have the opportunity to 
develop confidence in their own abilities to manage difficult situations and emotions.  
Only if we unmask psychopharmaceuticals, can we start to develop a more sensible 
relationship with them. Using drugs to alleviate emotional pain is not wrong, but it is fraught 
with difficulties. As well as the bodily aberrations they produce, drugs which affect brain 
functioning change the way we think and behave and relate to the world. Moreover, these 
changes are often difficult to appreciate while under the drug’s influence. In order to 
understand and minimise the potential damage that drugs can wreak, and to harness their 
effects for the good they can sometimes achieve, we need to explode the myth that the drugs 
prescribed for mental disorders work by correcting an underlying abnormality.  We need to 
recognise the real nature and purpose of these drugs, and acknowledge their lineage within 
the many ‘opiums’ of previous eras.   
 
  
 Table 1 Psychoactive effects of psychiatric drugs. 
Type of drug Psychoactive effects* 
 
Antipsychotics Sedation, subjective and objective cognitive 
slowing or impairment, emotional blunting/ 
indifference, reduced libido, demotivation, 
dysphoria (Healy and Farquhar 
1998;McClelland et al. 1990;Moncrieff, 
Cohen, & Mason 2009) 
Tricyclic antidepressants Sedation, cognitive impairment, dysphoria 
(Dumont et al. 2005;Herrmann and 
McDonald 1978) 
SSRIs and related antidepressants Drowsiness, lethargy, emotional blunting, 
loss of libido, ‘activation’ (agitation, 
irritability) (Bolling and Kohlenberg 
2004;Goldsmith & Moncrieff 2011;Price, 
Cole, & Goodwin 2009;Safer and Zito 2006) 
Lithium Sedation, cognitive impairment, lethargy, 
emotional blunting, dysphoria (Judd et al. 
1977a; judd et al, 1977b;Muller-
Oerlinghausen et al. 1979) 
Benzodiazepines Sedation, cognitive impairment, physical and 
mental relaxation,  euphoria 






Antidepressants Street drugs 
Antipsychotics Excess alcohol 
‘Mood stabilisers’  Nicotine 
Anti-ADHD drugs Barbiturates 
New anxiolytics (e.g. pregabalin) Benzodiazepines 
Substance misuse treatments  
  
 Figure 1: Trends in claimants of sickness and disability benefits by medical category 1995-
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